Analyst Price Target is $5.00
▲ +525.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Pulmatrix in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 525.00% upside from the last price of $0.80.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in Pulmatrix. This Buy consensus rating has held steady for over two years.
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.